



MINI REVIEW ARTICLE

Phytochemicals as weapons against drug resistance

Kruttika Jan¹, Medini K Deshpande¹, Stena Jesima Rebello¹, Keerthi G. Rao¹, Manikantan Pappuswamy^{1*}, Aditi Chaudhary¹, Kuppusamy Alagesan Paari¹, Joseph Kadanthottu Sebastian¹ & Karthick Kumar Alagamuthu²

¹Department of Life Sciences, Christ (Deemed to be University), Bangalore-560029, India

²Selvamm Arts and Science College (Autonomous), Namakkal, Tamilnadu

*Email: manikantan.p@christuniversity.in



OPEN ACCESS

ARTICLE HISTORY

Received: 10 March 2023

Accepted: 18 September 2023

Available online

Version 1.0 : 15 October 2023

Version 2.0 : 23 October 2023



Check for updates

Additional information

Peer review: Publisher thanks Sectional Editor and the other anonymous reviewers for their contribution to the peer review of this work.

Reprints & permissions information is available at https://horizonepublishing.com/journals/index.php/PST/open_access_policy

Publisher's Note: Horizon e-Publishing Group remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Indexing: Plant Science Today, published by Horizon e-Publishing Group, is covered by Scopus, Web of Science, BIOSIS Previews, Clarivate Analytics, NAAS, UGC Care etc. See https://horizonepublishing.com/journals/index.php/PST/indexing_abstracting

Copyright: © The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited (<https://creativecommons.org/licenses/by/4.0/>)

CITE THIS ARTICLE

Jan K, Deshpande M K, Rebello S J, Rao K G, Pappuswamy M, Chaudhary A, Paari KA, Sebastian J K, Alagamuthu K K. Phytochemicals as weapons against drug resistance. Plant Science Today. 2023; 10(sp2): 212-219. <https://doi.org/10.14719/pst.2495>

Abstract

Phytochemicals are plant-based products with high medicinal value. These metabolites effectively target disease-causing microbes. Drug-resistant pathogens have developed mechanisms to sustain themselves even with inhibitors. Drug resistance has emerged as a global giant, causing all available treatment options to fail. The solution to this problem is in the phytochemicals of plants with antibacterial and drug resistance modulation properties. Phytochemicals might be able to get rid of efflux pumps, drug-modulating enzymes, resistance genes, quorum sensing, and biofilm, all of which cause pathogens to be resistant to drugs. Moreover, anti-obesogenic and cardioprotective properties are also observed in phytochemicals. Additionally, studies show the success of phytochemical-based nanoparticles in drug resistance regulation. This review emphasizes phytochemicals' different mechanisms of action and their derivatives in curbing drug-resistant pathogens and cancer cells.

Keywords

ABC transporters; efflux pump modulation; Gram-negative bacteria; MDR; nano-biotics; PDR; uro-pathogens

Introduction

Phytochemicals are non-nutritive substances that have a protective function in plants against pathogenic attacks and environmental stress (1). Phytochemicals participate in secondary metabolism and do not have a role in the survival of plants. Plant secondary metabolites, i.e., phytochemicals, are divided into carotenoids, phenolics, alkaloids, N-containing compounds, and organosulfur compounds based on their biosynthetic origin (2) (Fig. 1.). Phytochemicals are featured by structural diversity and prominently act as antioxidant, antidiabetic, anticarcinogenic, antimicrobial, and anti-inflammatory. These chemicals efficiently disrupt disease causing signaling pathways.(3). Interestingly, phytochemicals have also been investigated for anti-obesogenic and cardioprotective properties (4,5).

Drug resistance is a significant threat in the treatment of diseases (6). The pressure to survive drives the appearance of drug resistance. Any pathogen or cancer cells capable of evolving and diversifying can develop resistance under the influence of inhibitors (7). Many drug-resistant bacterial strains, such as *Mycobacterium tuberculosis*, *Pseudomonas aeruginosa*, and *Staphylococcus aureus*, have failed all the available treatment options, making it impossible to control the disease (8). Along with bacterial infections, drug resistance is also seen in cancer cells (9). Cancer cells become resistant to chemotherapeutic drugs and continue to proliferate




Fig. 1. Classification of phytochemicals

inside the body despite the administration of drugs (10). According to the Centers for Disease Control and Prevention (CDC), antimicrobial resistance is a global public health threat, reporting the death of at least 1.27 million people worldwide and associated with nearly 5 million deaths in 2019(11). Bacteria can either naturally resist some antimicrobial agents or acquire resistance through various mechanisms (Fig. 2.). One such mechanism is accelerating the efflux of antibiotics through bacterial efflux pumps. Many efflux pump families and superfamilies are present namely, the ATP-binding cassette (ABC) superfamily, the resistance nodulation–cell-division superfamily, the major facilitator superfamily, the drug/metabolite transporter superfamily, the multidrug and toxic compound extrusion family, the proteobacterial antimicrobial compound efflux family, and the

p-aminobenzoic-glutamate transporter family (12). Other resistance-imparting pathways are plasmid resistance, changes in membrane permeability, alteration of the binding site, destruction of antibiotics, and quorum sensing followed by biofilm formation (13). The unsuitable usage of antibiotics has also resulted in antimicrobial resistance (14,15). European Center for Disease Prevention and Control, Centers for Disease Prevention and Control, and Infectious Diseases Society of America classify drug resistance into the following categories: extensive-drug resistance (XDR), pan-drug resistance (PDR), and multiple-drug resistance (MDR) (14). In XDR, bacteria remain sensitive to only one or two antibiotic categories, whereas in PDR, bacteria are resistant to all antimicrobial agents (16). The biggest threat is MDR, in which bacteria resist at least one agent in three or more antimicrobial classes (17).




Fig. 2. Mechanism for development of drug resistance in bacteria: A-Efflux pump, target modification, enzyme degradation, plasmid resistance, alteration in membrane permeability; B- Quorum sensing leading to biofilm formation

Multiple-drug resistance is also a significant obstacle in cancer chemotherapeutics. Mechanisms involved in cancer-related MDR can be pump resistance or non-pump resistance (18). Antiapoptotic defense is a non-pump resistance mechanism that utilizes BCL2 proteins. Pump resistance is associated with membrane-bound active efflux pumps. Efflux is majorly conducted by membrane transporters belonging to the ATP binding cassette (ABC) superfamily (19). Many ABC family genes have been identified and subcategorized into seven subfamilies, among which P-glycoprotein also MDR1/ABCB1, multidrug resistance-associated protein 1, and breast cancer resistance protein are considered as prime factors for induction of MDR (20).

Under such conditions, plant-derived compounds have always been the prime focus for a solution. Phytochemicals majorly target protein, DNA/RNA, lipids, and bio-membranes, causing inhibition of target pathogens. These secondary metabolites quench biofilm and quorum sensing and modulate efflux pumps, which are significantly involved in antimicrobial drug resistance (21). Anticancer drug resistance can also be tackled through phytochemicals by inhibiting proteins and signal transduction involved in anticancer drug resistance (22). The effectiveness of phytochemicals is improved through nanoparticles through various mechanisms like increasing the compound's bioavailability and improving phytochemical stability. Phytochemical-based nano-formulations have also contributed to combating drug resistance (23).

Collectively, phytochemicals have emerged as an effective way to tackle drug resistance in cancer and bacterial diseases. Drug resistance is challenging the available treatments and increasing the spread of diseases. Phytochemicals also show potential applications as anti-obesogenic and cardioprotective agents. The present review emphasizes different phytochemicals and their mechanisms of action against bacterial and cancer-related drug resistance, along with insights into the success of phytochemical-based nanoparticles in combating drug resistance.

Antimicrobial drug resistance coping through phytochemicals

Different phytochemical compounds have been studied for their drug resistance modulation properties in bacterial drug-resistant strains. The phytochemicals target various mechanisms of drug resistance development, which have been discussed below,

a. Biofilm and quorum quenching mechanism of phytochemicals

Quorum sensing (QS) and biofilm formation effectively participate in drug resistance. Quorum sensing is a density-dependent cell-cell communication system that controls many physiological behaviors in bacteria. Bacteria secrete signaling molecules that can regulate cellular processes involving bacterial luminescence and spore formation. Quorum sensing regulates efflux pump gene expression and biofilm formation, resulting in drug resistance (24). *Camellia sinensis*, commonly called green tea, constitutes phytochemicals that act as quorum-sensing inhibitors (25).

Firstly, the fraction with high bioactivity of green tea was characterized and then tested for its antibiofilm and quorum quenching ability on Gram-negative bacteria *Chromobacterium violaceum* ATCC 12472 (ATCC, USA), *Pseudomonas 138 aeruginosa*, and *Serratia marcescens* MTCC 97(MTCC, India). The ethyl acetate fraction of green tea was found to have the highest bioactive component, which exhibited antibiofilm production activity by turning off pilus assembly. The quorum quenching also took place due to the binding of phytochemicals to receptor proteins involved in quorum sensing (25). Multiple drug resistance is also seen in wound burn infections; many drug-resistant strains of fungi and Gram-positive and -negative bacteria have been noticed (26). Leaf extracts of *Lycium shawii* were investigated for modulating this resistance. The study conferred potential antimicrobial activities against clinical strains of PDR *Pseudomonas aeruginosa*, *Aspergillus niger*, *Staphylococcus aureus*, and, *Candida albicans*. Further, toxicological and hemolytic activity determination of the extract suggested that the extract is safe to be used in the subjects (27).

Pseudomonas aeruginosa is a pathogen accounting for 57 percent of nosocomial infections (28). Ethanolic leaf extract of *Syzygium jambos* was confirmed for anti-quorum sensing activity through binding to transcriptional activators of quorum sensing (29). Another study investigated the extract of *Acacia nilotica*, against quorum sensing-related virulence factors of *Pseudomonas aeruginosa* PAO1 and *Serratia marcescens* MTCC 97. Inhibition of biofilm was studied using microtiter plate assay and light microscopy. Extract components interacted with biofilm proteins, thus halting biofilm production. Further in vivo investigation is suggested (30).

b. Modulation of gene

Antibiotic resistance can also be facilitated by the mutation or horizontal transfer of resistance-conferring genes(31). Modulation of resistance gene expressions can happen at transcriptional or translational levels, thus helping the bacteria to cope with the stress (32). Different genes involved here can be targeted to get rid of the infection (33).

Gallic acid showed antimicrobial activity against *Shigella flexneri*, which invades colonic epithelium. Gallic acid regulates the expression of the mdoH gene and OpgH protein, which inhibits biofilm formation and controls its growth (34). Transcription profiling of Aloe-emodin, a phytochemical, showed an antibacterial effect by changing the genes involved in metabolism, membrane biosynthesis, and biofilm formation (35). Another Gram-negative bacteria, *Helicobacter pylori*, causes gastritis in humans and has also been reported as a carcinogen. Vacuolating cytotoxin (VacA) and cytotoxin-associated (CagA) genes confer pathogenicity to these bacteria. *Syzygium aromaticum* extracts were reported to modulate the CagA gene, in turn affecting PDR. The major constituent of the methanolic extract of *S. aromaticum* was found to be eugenol, a phenolic compound(36).

Genes responsible for enzyme synthesis can also be targeted for combating drug resistance. Versatile

mechanisms are involved in the development of resistance through enzymes. Enzymes target the antibiotic and prevent its action. Enzymes undergo structural changes which are the target of the antibiotic and thus surpass the effect of antibiotics (37). Nosocomial infections are a rising concern in the world, and one of the pathogens causing such infections is *Klebsiella pneumoniae*. Production of Carbapenemase and extended-spectrum beta-lactamase (ESBL), metallo beta-lactamase or ampicillinase (AmpC) enzymes causes drug resistance in this species. The research evaluated the inhibitory effect of crude ethyl extract (CEA) of *Andrographis paniculata* on the gene encoding AmpC beta-lactamase. It was observed that CEA stops the growth and biofilm production of the drug-resistant bacteria along with suppression of the AmpC gene (38).

c. Efflux pump modulation

An efflux pump is a bacterial system capable of excluding the toxins outside the cell. Using the exact mechanism, antimicrobial substances are thrown out of the cell, allowing the cell to survive. A large family of protein pumps is involved in this mechanism (39). AcrAB-TolC efflux pump confers MDR to *Salmonella enterica*, which is responsible for foodborne infections(40). A total of 71 phytocompounds derived from plants in Mexico, were tested for inhibition action against these pump proteins using molecular docking and molecular dynamics simulation techniques. Three compounds, 5-methoxypsoralen, licarin A, and naringenin (Fig. 3.), showed efflux pump inhibition activities. Licarin A showed the highest inhibition activity, supporting further research on its antimicrobial activities (41). Another investigation of catharanthine extracted from *Catharanthus roseous* showed its potential to reverse the drug resistance. The study was done in silico, which revealed the MexA, MexB, and OprM pump protein inhibition mechanism of the catharanthine (42).

Anticancer drug resistance modulation using phytochemicals-

One of the world's challenges is to tackle drug-resistant cancer cells. Studies done using phytochemicals in cancer focus on two aspects: to reverse the drug's effect by




Fig. 3. Phytochemicals which have potential to tackle drug resistant pathogens

affecting the expression of ABC transporter proteins and to exert combined interactions with anticancer drugs (43). A study revolving around the cytotoxicity check of phytochemicals against MDR bladder cancer cells suggested, that capsaicin has a synergistic cytotoxic effect against drug-resistant cancer cells (44). The gemcitabine drug, resistant cell line, T-24 GCB, was used in the study. In bladder cancer cells, drug resistance is caused due to membranous ABCC2 (ATP binding cassette subfamily C member 2), cytoplasmic DCK (Deoxycytidine kinase), and TKs (thymidine kinases) expression. Many phytochemicals such as curcumin, capsaicin, resveratrol, and quercetin, along with gemcitabine, were assessed through 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Also, capsaicin and quercetin alone and combined with gemcitabine reduced the expression of resistant-causing factors (45).

P-glycoprotein (P-gp/MDR1/ABCB1), belonging to ABC transporter proteins leading to MDR has also been extensively studied. To this, combating strategies involve the co-administration of synthetic or natural protein modulators, but studies to confirm the non-toxicity of these modulators are still in process (46). A phytochemical study of *Euphorbia boetica* showed the presence of P-gp modulators. This plant species contains- unique macrocyclic diterpenes having lathyrane and jatrophane skeletons known as MDR modulators (47). This study involved chromatographic separation and further analysis of fractions using H-NMR to find the compounds having macrocyclic diterpenes. Using transport assays, and chemosensitivity assays, in mouse model and Colo320 cell models MDR reversal activity was examined. As per the study, macrocyclic diterpenes have MDR reversal activity; additionally, it was noted that combining such compounds with antineoplastic drugs synergistically enhances their effect (48). Another phytochemical compound, cinnamophilin (Fig. 3.) isolated from *Cinnamomum philippinense*, also reported P-gp inhibition thus cancer MDR reversal and drug resensitization. This compound is a dual allosteric inhibitor of the protein through an ATPase binding pocket and drug binding pocket (49).

Other processes such as Epithelial-mesenchymal transition (EMT) pathways are also involved in drug resistance (50). Epithelial cells change to mesenchymal cells and gain fibroblast-like characteristics, through the EMT process. Natural products have been reported to reverse EMT and prevent drug resistance (51). One of the studies on Ferrerol also suggested EMT ablation in lung squamous cell carcinoma cells (52). These studies, showed successful coping of drug resistance in cancer using phytochemicals.

Phytochemical-based nanoparticles application in drug resistance modulation-

Nanotechnology has gained increased applications in combating drug resistance. Studies suggest the positive effect of nanoparticles, thus establishing nanoparticles (NPs) as a -'nanobiotic'(53). Nanoparticles made using biological synthesis reduce the release of toxic by-products after production. One such method for the synthesis and stabilization of nanoparticles is the usage of phytochemicals as capping agents (54). US FDA (Food and

Drug Administration) lists zinc oxide nanoparticles under GRAS (Generally recognized as safe) metal oxide(55). These nanoparticles have drug delivery ability and show antifungal, antibacterial, antidiabetic, anticancer, and antioxidant properties. The study under consideration focused on the application of these NPs along with *Bryophyllum pinnatum* leaf extract as a capping agent, to treat drug-resistant strains of uropathogens. After characterizing synthesized nanoparticles, the antibacterial potential was analyzed using the agar disc diffusion method against clinical Gram-negative uropathogens. The assay confirmed the antibacterial activity of NPs against MDR strains, thus opening a new dimension in nanoantibiotics (56). Another green synthesized metal nanoparticle was studied against antibiotic-resistant *Pseudomonas aeruginosa*. *Cinnamomum tamala* (Tejpata) leaf extract-derived silver nanoparticles (AgNPs) were subjected to molecular characterization using spectroscopic and microscopic techniques followed by antibacterial activity testing using the agar disc diffusion method. Zones of inhibition on agar plates confirmed the required effect of synthesized AgNPs. The inhibitory effect of leaf extract was found to be enhanced by the addition of AgNPs (57).

Another instance showed combinatorial therapy success towards antibacterial resistance combat. Conventional antibiotic combined with embelin-loaded, chitosan-gold NPs were checked for antibacterial activity against MDR-resistant strains of *Pseudomonas aeruginosa* and *Escherichia coli*. The synergistic activity of NPs with conventional antibiotics displayed an inhibitory effect against the pathogens. Molecular docking revealed the efflux pump inhibition mechanism, wherein Emb and efflux pump-related proteins were noted. Therefore, the bacteria retained the antibiotic, causing the organism's death. Such formulations of phytochemical and metallic nanoparticles along with antibiotics, can also be applied to other MDR-resistant strains (58). Not only antibacterial resistance but many studies suggest the effectiveness of phytochemicals and nanoparticles in anticancer resistance

medication. One of the studies suggested the cytotoxic effect of lactoferrin-associated Betulinic acid nanoparticles in laryngeal and triple-negative breast cancer types. Betulinic acid, a triterpenoid is extensively found in *Betula alba's* bark. Two cell lines used for the study were HEP-2 and MDA-MB-231. Synthesized nanoparticles achieved faster cellular uptake and induction of cellular death at much lower concentrations than previous reports. The study confirmed the ability of phytochemical-based nanoparticles in drug-resistant cancers (59).

Summarizing some of the phytochemical-based studies and their mechanism of action in microbial diseases and cancer in Table 1.

Anti-obesogenic and cardioprotective potentials of phytochemicals-

As the antibacterial and anticancer drugs face the issue of resistance, available anti-obesogenic drugs are of low efficacy, show undesirable side effects, and result in short-term weight loss. Through various studies, phytochemicals have also been identified as preventives and therapeutics for obesity (68). A study suggested that the anti-obesogenic property of curcumin is conferred by its ability to induce apoptosis in preadipocytes and inhibit preadipocyte differentiation, thus blocking adipogenesis (69). Another study on *Allium*-derived propyl propane thiosulphinate(PTS), confirmed PTS as an anti-obesogenic and protective agent. This chemical prevented weight gain, decreased adipocyte size, and also changed lipid metabolism, and increased thermogenic capacity markers of brown adipose tissue (70). Reduction in the expression of proteins responsible for adipogenesis and raising the expression of fatty acid oxidation proteins results in the anti-obesogenic character of broccoli sprout powder and *Sinapis alba* L. seed powder. Moreover, activation of the AMPK signaling pathway also helps in weight loss (71). Many other mechanisms involving stimulation of thermogenesis, promoting lipolysis, and inhibiting hypothalamic enzymes have been established in

Table 1. Preclinical studies of phytochemicals showing resistance modulation activity in microbial diseases and cancer

Genus/Species	Phytochemical in study	Therapeutic agent	Disease/Infections	Strategy adapted/ Mechanism of action	References
<i>Olea europaea</i> L.	Olive	Metformin	All types of breast cancer	Through p53-independent apoptosis, the viability of MCF-7 reduced synergistically.	(60)
<i>Plumbago zeylanica</i> L.	Plumbagin	Cisplatin	Tongue squamous cell carcinoma	Apoptosis through activation of JNK, Suppression of cell viability, and repression of AKT/mTOR signaling pathways synergistically	(61)
<i>Allium sativum</i> L	Allicin	5-Fluorouracil	Colorectal and lung Carcinoma	In comparison with single-agent IC50, enhanced cytotoxic activity in half of their IC50.	(62)
<i>Scrophularianodosa</i>	Diosmin	Dactolisib	Colorectal cancer	For Dactolisib and Diosmin, induction of apoptosis at IC50 of 1µM and 250µM respectively.	(63)
Mulberries, Peanuts, Grapes	Resveratrol	Docetaxel	Prostate cancer	Suppressed cell growth with a rise in the sub-G0/G1 peak, ROS, and mitochondrial dysfunction synergistically.	(64)
<i>Citrus lemon</i>	Limonene	D-Limonene	Abscesses (boils), furuncles, and cellulitis	Disrupts cell membrane integrity.	(65)
<i>Thymus vulgaris</i> L.	Thymol	p-cymene	Candidiasis	Disturbance in efflux pump, inhibition of H (+)-ATPase in the cell membrane and cytoplasmic membrane	(66)
<i>Cymbopogon</i>	Citronellol	-	Athlete's foot, Tinea pedis, breast cancer.	Apoptosis in MCF-7 and MDA-MB-231 by mitochondrial-mediated activation in human mammary tumour cell lines.	(67)

phytochemicals, proving their anti-obesogenic properties (72).

Obesity is a multifaceted disorder that can be linked to the emergence of other diseases, such as cardiovascular diseases (73). Phytochemicals have also been instrumental in this perspective to protect the individual from cardiovascular diseases. A recent study on phytochemicals of *Morus nigra* (*M. nigra*) fruit showed that phytochemical extracts of this fruit can increase antioxidant enzymes, reduce transaminases, lactate dehydrogenase, lipids, liver and also blood pressure, contributing to its cardio-protective nature (74). Another study using rat animal models of chicory acid extract from Romanian chicory (*Chicory intybus*) gave promising results in curing myocardial ischemia (75). Icariin and associated metabolites also have a protective nature towards myocardial cells (76).

Conclusion and Future Perspectives

Phytochemicals are an essential part of the biodiversity available on the earth. Phytochemicals show an enormous scope in managing the drug resistance problem in microbial diseases and cancer. These plant-based products show inhibitory effects on resistance-causing genes, efflux pump proteins, quorum sensing, and biofilm formation in microbial drug resistance strains. Concerning cancer-drug resistance coping, many phytochemicals target ABC transporter proteins. Phytochemical-based nanoparticles synergistically improve the therapeutic effect of phytochemicals, thus emerging as a promising solution. Cardioprotective and anti-obesogenic characteristics of these plant-based derivatives have also been recognized. A shift from chemical-based antibiotics to phytochemical-based nano-biotics can successfully tackle the drug resistance. More such studies of effective extraction strategies and characterization of phytochemicals will help mankind to access efficient and cost-effective treatment options. It is also important to note that, most of the studies are yet to reach animal model in-vivo studies, and drug testing has not even started. Clinical trials should be undertaken to confirm the safety, drug efficacy, and metabolomics of phytochemical-based nanoparticle drugs. The gap between knowledge and application is persisting, requiring extensive research in commercializing phytochemical-based drugs.

Acknowledgements

The authors would like to take this opportunity to thank the university for all of the assistance it gave, which included direction, critical evaluations, software tools, and on top of all of that, constructive ideas whenever they were requested.

Authors' contributions

KJ devised the article, searched the literature, wrote the manuscript and plotted figures. MP, KAP and JKS revised the work. MD, SJR, AC, and KA searched and supplemented the literature. MP conceived of the study

and participated in its design and coordination. All authors read and approved the final manuscript.

Compliance with ethical standards

Conflict of interest: Authors do not have any conflict of interest to declare.

Ethical approvals: None.

References

1. Yang L, Wen KS, Ruan X, Zhao YX, Wei F, Wang Q. Response of plant secondary metabolites to environmental factors. *Molecules*. 2018;23(4):762.
2. Sharma A, Sharma S, Kumar A, Kumar V, Sharma AK. Plant secondary metabolites: An introduction of their chemistry and biological significance with physicochemical aspect. In *Plant Secondary Metabolites: Physico-Chemical Properties and Therapeutic Applications 2022* pp. 1-45. Singapore: Springer Nature Singapore. https://doi.org/10.1007/978-981-16-4779-6_1
3. Roy M, Datta A. Fundamentals of Phytochemicals. In: Roy M, Datta A, editors. *Cancer Genetics and Therapeutics: Focus on Phytochemicals* [Internet]. Singapore: Springer; 2019 p. 49–81. Available from: https://doi.org/10.1007/978-981-13-9471-3_3
4. Bansal A, Priyadarsini C, Bansal A, Priyadarsini C. Medicinal Properties of Phytochemicals and Their Production. In: *Natural Drugs from Plants*. IntechOpen; 2021. Available from: <https://www.intechopen.com/chapters/77565>
5. Pagliaro B, Santolamazza C, Simonelli F, Rubattu S. Phytochemical Compounds and Protection from Cardiovascular Diseases: A State of the Art. *BioMed Res Int*. 2015;2015:e918069.
6. Antimicrobial resistance [Internet]. Available from: <https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance> [cited 2023 Sep 17]
7. Kurt Yilmaz N, Schiffer CA. Introduction: Drug Resistance. *Chem Rev*. 2021;121(6):3235–7.
8. Suganya T, Packiavathy IA, Aseervatham G, Carmona A, Rashmi V, Mariappan S, Devi NR, Ananth DA. Tackling multiple-drug-resistant bacteria with conventional and complex phytochemicals. *Frontiers in Cellular and Infection Microbiology*. 2022;12:883839.
9. Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. *Nature*. 2019;575(7782):299–309.
10. Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The Different Mechanisms of Cancer Drug Resistance: A Brief Review. *Adv Pharm Bull*. 2017;7(3):339–48.
11. Centers for Disease Control and Prevention (U.S.). Antibiotic resistance threats in the United States, 2019 [Internet]. Centers for Disease Control and Prevention (U.S.); 2019 Nov [cited 2023 Feb 27]. Available from: <https://stacks.cdc.gov/view/cdc/82532>
12. Henderson PJF, Maher C, Elbourne LDH, Eijkelkamp BA, Paulsen IT, Hassan KA. Physiological Functions of Bacterial “Multidrug” Efflux Pumps. *Chem Rev*. 2021;121(9):5417–78.
13. Yadav H, Mahalvar A, Pradhan M, Yadav K, Kumar Sahu K, Yadav R. Exploring the potential of phytochemicals and nanomaterial: A boon to antimicrobial treatment. *Med Drug Discov*. 2023;17:100151.
14. Tiwari P, Khare T, Shiram V, Bae H, Kumar V. Plant synthetic biology for producing potent phyto-antimicrobials to combat antimicrobial resistance. *Biotechnol Adv*. 2021;48:107729.

15. Khare T, Anand U, Dey A, Assaraf YG, Chen ZS, Liu Z, Kumar V. Exploring phytochemicals for combating antibiotic resistance in microbial pathogens. *Frontiers in pharmacology*. 2021;12:720726.
16. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect*. 2012;18(3):268–81.
17. Jubair N, Rajagopal M, Chinnappan S, Abdullah NB, Fatima A. Review on the Antibacterial Mechanism of Plant-Derived Compounds against Multidrug-Resistant Bacteria (MDR). *Evid Based Complement Alternat Med*. 2021;2021:e3663315.
18. Bukowski K, Kciuk M, Kontek R. Mechanisms of Multidrug Resistance in Cancer Chemotherapy. *Int J Mol Sci*. 2020;21(9):3233.
19. Juan-Carlos PDM, Perla-Lidia PP, Stephanie-Talia MM, Mónica-Griselda AM, Luz-María TE. ABC transporter superfamily. An updated overview, relevance in cancer multidrug resistance and perspectives with personalized medicine. *Mol Biol Rep*. 2021;48(2):1883–901.
20. Kumar A, Jaitak V. Natural products as multidrug resistance modulators in cancer. *Eur J Med Chem*. 2019;176:268–91.
21. Wink M. Current Understanding of Modes of Action of Multicomponent Bioactive Phytochemicals: Potential for Nutraceuticals and Antimicrobials. *Annu Rev Food Sci Technol*. 2022;13(1):337–59.
22. Roy M, Datta A, Roy M, Datta A. Improvement of Cancer Therapy Using Phytochemicals. *Cancer Genetics and Therapeutics: Focus on Phytochemicals*. 2019:139–64.
23. Recent advances in phytochemical-based Nano-formulation for drug-resistant Cancer. *Med Drug Discov*. 2021;10:100082.
24. Zhao X, Yu Z, Ding T. Quorum-Sensing Regulation of Antimicrobial Resistance in Bacteria. *Microorganisms*. 2020;8(3):425.
25. Qais FA, Khan MS, Ahmad I. Broad-spectrum quorum sensing and biofilm inhibition by green tea against gram-negative pathogenic bacteria: Deciphering the role of phytochemicals through molecular modelling. *Microb Pathog*. 2019;126:379–92.
26. Robben PM, Ayalew MD, Chung KK, Ressler RA. Multi-Drug-Resistant Organisms in Burn Infections. *Surg Infect*. 2021 Feb;22(1):103–12.
27. Ali SS, El-Zawawy NA, Al-Tohamy R, El-Sapagh S, Mustafa AM, Sun J. *Lycium shawii* Roem. & Schult.: A new bioactive antimicrobial and antioxidant agent to combat multi-drug/pan-drug resistant pathogens of wound burn infections. *J Tradit Complement Med*. 2020;10(1):13–25.
28. Qin S, Xiao W, Zhou C, Pu Q, Deng X, Lan L, et al. *Pseudomonas aeruginosa*: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. *Signal Transduct Target Ther*. 2022;7(1):1–27.
29. Rajkumari J, Borkotoky S, Murali A, Busi S. Anti-quorum sensing activity of *Syzygium jambos* (L.) Alston against *Pseudomonas aeruginosa* PAO1 and identification of its bioactive components. *South Afr J Bot*. 2018;118:151–7.
30. Samreen, Qais FA, Ahmad I. Anti-quorum sensing and biofilm inhibitory effect of some medicinal plants against gram-negative bacterial pathogens: in vitro and in silico investigations. *Heliyon*. 2022;8(10):e11113.
31. Hughes D, Andersson DI. Environmental and genetic modulation of the phenotypic expression of antibiotic resistance. *FEMS Microbiol Rev*. 2017;41(3):374–91.
32. Depardieu F, Podglajen I, Leclercq R, Collatz E, Courvalin P. Modes and Modulations of Antibiotic Resistance Gene Expression. *Clin Microbiol Rev*. 2007;20(1):79–114.
33. Moriguchi K, Zoolkefli FIRM, Abe M, Kiyokawa K, Yamamoto S, Suzuki K. Targeting Antibiotic Resistance Genes Is a Better Approach to Block Acquisition of Antibiotic Resistance Than Blocking Conjugal Transfer by Recipient Cells: A Genome-Wide Screening in *Escherichia coli*. *Front Microbiol*. 2020;10:2939.
34. Kang J, Liu L, Liu M, Wu X, Li J. Antibacterial activity of gallic acid against *Shigella flexneri* and its effect on biofilm formation by repressing *mdoH* gene expression. *Food Control*. 2018;94:147–54.
35. Li T, Lu Y, Zhang H, Wang L, Beier RC, Jin Y, Wang W, Li H, Hou X. Antibacterial activity and membrane-targeting mechanism of aloe-emodin against *Staphylococcus epidermidis*. *Frontiers in Microbiology*. 2021;12:621866.
36. El-Shouny WA, Ali SS, Hegazy HM, Abd Elnabi MK, Ali A, Sun J. *Syzygium aromaticum* L. Traditional herbal medicine against *cagA* and *vacA* toxin genes-producing drug resistant *Helicobacter pylori*. *J Tradit Complement Med*. 2020;10(4):366–77.
37. Egorov AM, Ulyashova MM, Rubtsova MYu. Bacterial Enzymes and Antibiotic Resistance. *Acta Naturae*. 2018;10(4):33–48.
38. Sah SK, Rasool U, Hemalatha S. *Andrographis paniculata* extract inhibit growth, biofilm formation in multidrug resistant strains of *Klebsiella pneumoniae*. *J Tradit Complement Med*. 2020;10(6):599–604.
39. Mohanty H, Pachpute S, Yadav RP. Mechanism of drug resistance in bacteria: efflux pump modulation for designing of new antibiotic enhancers. *Folia Microbiol (Praha)*. 2021;66(5):727–39.
40. Du D, Wang-Kan X, Neuberger A, van Veen HW, Pos KM, Piddock LJV, et al. Multidrug efflux pumps: structure, function and regulation. *Nat Rev Microbiol*. 2018;16(9):523–39.
41. Oyedara OO, Fadare OA, Franco-Frías E, Heredia N, García S. Computational assessment of phytochemicals of medicinal plants from Mexico as potential inhibitors of *Salmonella enterica* efflux pump AcrB protein. *J Biomol Struct Dyn*. 2023;41(5):1776–89.
42. Dwivedi GR, Tyagi R, Sanchita, Tripathi S, Pati S, Srivastava SK, Darokar MP, Sharma A. Antibiotics potentiating potential of catharanthine against superbug *Pseudomonas aeruginosa*. *Journal of Biomolecular Structure and Dynamics*. 2018;36(16):4270–84.
43. Tinoush B, Shirdel I, Wink M. Phytochemicals: Potential Lead Molecules for MDR Reversal. *Front Pharmacol*. 2020;11:832.
44. Ranjan A, Ramachandran S, Gupta N, Kaushik I, Wright S, Srivastava S, et al. Role of Phytochemicals in Cancer Prevention. *Int J Mol Sci*. 2019;20(20):4981.
45. Cho CJ, Yu CP, Wu CL, Ho JY, Yang CW, Yu DS. Decreased drug resistance of bladder cancer using phytochemicals treatment. *Kaohsiung J Med Sci*. 2021;37(2):128–35.
46. Mora Lagares L, Novič M. Recent Advances on P-Glycoprotein (ABCB1) Transporter Modelling with In Silico Methods. *International Journal of Molecular Sciences*. 2022;23(23):14804.
47. Kemboi D, Siwe-Noundou X, Krause RW, Langat MK, Tembu VJ. Euphorbia diterpenes: An update of isolation, structure, pharmacological activities and structure-activity relationship. *Molecules*. 2021;26(16):5055.
48. Neto S, Duarte N, Pedro C, Spengler G, Molnár J, Ferreira MJU. Effective MDR reversers through phytochemical study of *Euphorbia boetica*. *Phytochem Anal*. 2019;30(5):498–511.

49. Teng YN, Huang BH, Huang SY, Wu IT, Wu TS, Lee TE, et al. Cinnamophilin overcomes cancer multi-drug resistance via allosterically modulating human P-glycoprotein on both drug binding sites and ATPase binding sites. *Biomed Pharmacother.* 2021;144:112379.
50. Debnath P, Huirem RS, Dutta P, Palchaudhuri S. Epithelial-mesenchymal transition and its transcription factors. *Biosci Rep.* 2022;42(1):BSR20211754.
51. Dahmardeh Ghalehno A, Boustan A, Abdi H, Aganj Z, Mosaffa F, Jamialahmadi K. The Potential for Natural Products to Overcome Cancer Drug Resistance by Modulation of Epithelial-Mesenchymal Transition. *Nutr Cancer.* 2022;74(8):2686–712.
52. Farrerol overcomes the invasiveness of lung squamous cell carcinoma cells by regulating the expression of inducers of epithelial mesenchymal transition. *Microb Pathog.* 2019;131:278–82.
53. Chakraborty N, Jha D, Roy I, Kumar P, Gaurav SS, Marimuthu K, et al. Nanobiotics against antimicrobial resistance: harnessing the power of nanoscale materials and technologies. *J Nanobiotechnology.* 2022;20(1):375.
54. Role of capping agents in the application of nanoparticles in biomedicine and environmental remediation: recent trends and future prospects - PubMed [Internet]. [cited 2023 Sep 17]. Available from: <https://pubmed.ncbi.nlm.nih.gov/33225973/>
55. Anjum S, Hashim M, Malik SA, Khan M, Lorenzo JM, Abbasi BH, et al. Recent Advances in Zinc Oxide Nanoparticles (ZnO NPs) for Cancer Diagnosis, Target Drug Delivery, and Treatment. *Cancers.* 2021;13(18):4570.
56. Jagdish R, Nehra K. *Bryophyllum pinnatum* mediated synthesis of zinc oxide nanoparticles: characterization and application as biocontrol agents for multi-drug-resistant uropathogens. *Heliyon.* 2022;8(10):e11080.
57. Al Mashud MdA, Moinuzzaman Md, Hossain MdS, Ahmed S, Ahsan G, Reza A, et al. Green synthesis of silver nanoparticles using *Cinnamomum tamala* (Tejpata) leaf and their potential application to control multidrug resistant *Pseudomonas aeruginosa* isolated from hospital drainage water. *Heliyon.* 2022;8(7):e09920.
58. Khare T, Mahalunkar S, Shriram V, Gosavi S, Kumar V. Embelin-loaded chitosan gold nanoparticles interact synergistically with ciprofloxacin by inhibiting efflux pumps in multidrug-resistant *Pseudomonas aeruginosa* and *Escherichia coli*. *Environ Res.* 2021;199:111321.
59. Halder A, Jethwa M, Mukherjee P, Ghosh S, Das S, Helal Uddin ABM, et al. Lactoferrin-tethered betulinic acid nanoparticles promote rapid delivery and cell death in triple negative breast and laryngeal cancer cells. *Artif Cells Nanomedicine Biotechnol.* 2020 1;48(1):1362–71.
60. Isleem RM, Alzaharna MM, Sharif FA. Synergistic anticancer effect of combining metformin with olive (*Olea europaea* L.) leaf crude extract on the human breast cancer cell line MCF-7. *J Med Plants* 2020;8(2):30-7.
61. Plumbagin Enhances the Anticancer Efficacy of Cisplatin by Increasing Intracellular ROS in Human Tongue Squamous Cell Carcinoma [Internet]. [cited 2023 Feb 27]. Available from: <https://www.hindawi.com/journals/omcl/2020/5649174/>
62. Țigu AB, Toma VA, Moț AC, Jurj A, Moldovan CS, Fischer-Fodor E, et al. The Synergistic Antitumor Effect of 5-Fluorouracil Combined with Allicin against Lung and Colorectal Carcinoma Cells. *Molecules.* 2020;25(8):1947.
63. The synergistic anti-proliferative effect of the combination of diosmin and BEZ-235 (dactolisib) on the HCT-116 colorectal cancer cell line occurs through inhibition of the PI3K/Akt/mTOR/NF-κB axis | SpringerLink [Internet]. [cited 2023 Feb 27]. Available from: <https://link.springer.com/article/10.1007/s11033-020-05327-4>
64. Lee SH, Lee YJ. Synergistic anticancer activity of resveratrol in combination with docetaxel in prostate carcinoma cells. *Nutr Res Pract.* 2020;15(1):12–25.
65. Konuk HB, Ergüden B. Phenolic –OH group is crucial for the antifungal activity of terpenoids via disruption of cell membrane integrity. *Folia Microbiol (Praha).* 2020;65(4):775–83.
66. Sharifzadeh A, Khosravi AR, Shokri H, Shirzadi H. Potential effect of 2-isopropyl-5-methylphenol (thymol) alone and in combination with fluconazole against clinical isolates of *Candida albicans*, *C. glabrata* and *C. krusei*. *J Mycol Médicale.* 2018;28(2):294–9.
67. Pumival P, Tadtong S, Athikomkulchai S, Chittasupho C. Antifungal Activity and the Chemical and Physical Stability of Microemulsions Containing Citrus hystrix DC Leaf Oil. *Nat Prod Commun.* 2020;15(9):1934578X20957755.
68. Murugan DD, Balan D, Wong P. Adipogenesis and therapeutic potentials of antiobesogenic phytochemicals: Insights from preclinical studies. *Phytother Res.* 2021;35(11):5936–60.
69. Wu LY, Chen CW, Chen LK, Chou HY, Chang CL, Juan CC. Curcumin Attenuates Adipogenesis by Inducing Preadipocyte Apoptosis and Inhibiting Adipocyte Differentiation. *Nutrients.* 2019;11(10):2307.
70. Liébana-García R, Olivares M, Rodríguez-Ruano SM, Tolosa-Enguís V, Chulia I, Gil-Martínez L, et al. The Allium Derivate Propyl Propane Thiosulfinate Exerts Anti-Obesogenic Effects in a Murine Model of Diet-Induced Obesity. *Nutrients.* 2022;14(3):440.
71. Men X, Han X, Lee SJ, Oh G, Park KT, Han JK, et al. Anti-Obesogenic Effects of Sulforaphane-Rich Broccoli (Brassica oleracea var. italica) Sprouts and Myrosinase-Rich Mustard (*Sinapis alba* L.) Seeds In Vitro and In Vivo. *Nutrients.* 2022;14(18):3814.
72. Saad B, Ghareeb B, Kmail A. Metabolic and Epigenetics Action Mechanisms of Antiobesity Medicinal Plants and Phytochemicals. *Evid-Based Complement Altern Med ECAM.* 2021;2021:9995903.
73. Ahmad B, Friar EP, Vohra MS, Garrett MD, Serpell CJ, Fong IL, et al. Mechanisms of action for the anti-obesogenic activities of phytochemicals. *Phytochemistry.* 2020;180:112513.
74. Phytochemical characterization of *Morus nigra* fruit ultrasound-assisted ethanolic extract for its cardioprotective potential - Maqsood - 2022 - Journal of Food Biochemistry - Wiley Online Library [Internet]. [cited 2023 Sep 17]. Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1111/jfbc.14335>
75. Epure A, Pârvu AE, Vlase L, Benedec D, Hanganu D, Gheldiu AM, et al. Phytochemical Profile, Antioxidant, Cardioprotective and Nephroprotective Activity of Romanian Chicory Extract. *Plants.* 2021;10(1):64.
76. Zeng Y, Xiong Y, Yang T, Wang Y, Zeng J, Zhou S, et al. Icaritin and its metabolites as potential protective phytochemicals against cardiovascular disease: From effects to molecular mechanisms. *Biomed Pharmacother.* 2022;147:112642.